A detailed history of Bridgefront Capital, LLC transactions in Charles River Laboratories International, Inc. stock. As of the latest transaction made, Bridgefront Capital, LLC holds 3,831 shares of CRL stock, worth $619,242. This represents 0.3% of its overall portfolio holdings.

Number of Shares
3,831
Previous 2,662 43.91%
Holding current value
$619,242
Previous $549,000 37.34%
% of portfolio
0.3%
Previous 0.23%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$187.96 - $245.29 $219,725 - $286,744
1,169 Added 43.91%
3,831 $754,000
Q2 2024

Aug 14, 2024

BUY
$206.39 - $268.73 $549,410 - $715,359
2,662 New
2,662 $549,000
Q3 2023

Nov 14, 2023

BUY
$194.44 - $217.61 $393,352 - $440,225
2,023 New
2,023 $396,000
Q1 2023

May 15, 2023

BUY
$191.89 - $259.92 $350,391 - $474,613
1,826 New
1,826 $368,000
Q2 2022

Aug 12, 2022

BUY
$204.13 - $302.4 $231,891 - $343,526
1,136 New
1,136 $243,000

Others Institutions Holding CRL

About CHARLES RIVER LABORATORIES INTERNATIONAL, INC.


  • Ticker CRL
  • Exchange NYSE
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 50,863,300
  • Market Cap $8.22B
  • Description
  • Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Ass...
More about CRL
Track This Portfolio

Track Bridgefront Capital, LLC Portfolio

Follow Bridgefront Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgefront Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bridgefront Capital, LLC with notifications on news.